Cancer Immunotherapies Market - Global Professional Analysis and Forecast to 2026
- REPORT SUMMARY
- TABLE OF CONTENTS
- INDUSTRY COVERAGE
The worldwide Cancer Immunotherapies market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.1% during the forecast period.
This report presents the market size and development trends by detailing the Cancer Immunotherapies market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Cancer Immunotherapies market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Cancer Immunotherapies industry and will help you to build a panoramic view of the industrial development.
Cancer Immunotherapies Market, By Type:
Monoclonal Antibodies
Cytokines & Immunomodulators
Others
Cancer Immunotherapies Market, By Application:
Hospitals
Cancer Research Centers
Clinics
Some of the leading players are as follows:
Seattle Genetics
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Amgen Inc.
Celgene
Celldex Therapeutics
Incyte Corporation
Advaxis Inc.
Gilead Sciences
Astrazeneca plc.
Immunomedics Inc.
Merck & Co., Inc.
Bayer AG
Pfizer Inc.
Peregrine Pharmaceuticals
Eli Lilly and Company
Novartis AG
Bluebird bio
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Cancer Immunotherapies Market: Technology Type Analysis
-
4.1 Cancer Immunotherapies Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Cancer Immunotherapies Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Monoclonal Antibodies
4.3.2 Cytokines & Immunomodulators
4.3.3 Others
5 Cancer Immunotherapies Market: Product Analysis
-
5.1 Cancer Immunotherapies Product Market Share Analysis, 2018 & 2026
-
5.2 Cancer Immunotherapies Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Cancer Immunotherapies Market: Application Analysis
-
6.1 Cancer Immunotherapies Application Market Share Analysis, 2018 & 2026
-
6.2 Cancer Immunotherapies Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospitals
6.3.2 Cancer Research Centers
6.3.3 Clinics
7 Cancer Immunotherapies Market: Regional Analysis
-
7.1 Cancer Immunotherapies Regional Market Share Analysis, 2018 & 2026
-
7.2 Cancer Immunotherapies Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Seattle Genetics
9.1.1 Seattle Genetics Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 F. Hoffmann-La Roche AG
9.2.1 F. Hoffmann-La Roche AG Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Bristol-Myers Squibb Company
9.3.1 Bristol-Myers Squibb Company Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Amgen Inc.
9.4.1 Amgen Inc. Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Celgene
9.5.1 Celgene Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Celldex Therapeutics
9.6.1 Celldex Therapeutics Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Incyte Corporation
9.7.1 Incyte Corporation Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Advaxis Inc.
9.8.1 Advaxis Inc. Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Gilead Sciences
9.9.1 Gilead Sciences Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Astrazeneca plc.
9.10.1 Astrazeneca plc. Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Immunomedics Inc.
9.11.1 Immunomedics Inc. Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Merck & Co., Inc.
9.12.1 Merck & Co., Inc. Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Bayer AG
9.13.1 Bayer AG Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Pfizer Inc.
9.14.1 Pfizer Inc. Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Peregrine Pharmaceuticals
9.15.1 Peregrine Pharmaceuticals Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Eli Lilly and Company
9.16.1 Eli Lilly and Company Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
9.17 Novartis AG
9.17.1 Novartis AG Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis
9.18 Bluebird bio
9.18.1 Bluebird bio Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
9.18.5 SWOT analysis
The List of Tables and Figures (Totals 61 Figures and 145 Tables)
Figure Monoclonal Antibodies Cancer Immunotherapies market, 2015 - 2026 (USD Million)
Figure Cytokines & Immunomodulators Cancer Immunotherapies market, 2015 - 2026 (USD Million)
Figure Others Cancer Immunotherapies market, 2015 - 2026 (USD Million)
Figure Hospitals market, 2015 - 2026 (USD Million)
Figure Cancer Research Centers market, 2015 - 2026 (USD Million)
Figure Clinics market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Cancer Immunotherapies market, by country, 2015 - 2026 (USD Million)
-
Table North America Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table North America Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table North America Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Canada Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Canada Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Europe Cancer Immunotherapies market, by country, 2015 - 2026 (USD Million)
-
Table Europe Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Europe Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Europe Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Germany Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Germany Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table France Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table France Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Italy Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Italy Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Spain Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Spain Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Immunotherapies market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table China Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table China Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Japan Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Japan Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table India Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table India Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Immunotherapies market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table MEA Cancer Immunotherapies market, by country, 2015 - 2026 (USD Million)
-
Table MEA Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table MEA Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table MEA Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Cancer Immunotherapies market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Cancer Immunotherapies market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Cancer Immunotherapies market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Seattle Genetics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table F. Hoffmann-La Roche AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Company Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Amgen Inc. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Celgene Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Celldex Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Incyte Corporation Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Advaxis Inc. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Gilead Sciences Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Astrazeneca plc. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Immunomedics Inc. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck & Co., Inc. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bayer AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Inc. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Peregrine Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eli Lilly and Company Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bluebird bio Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Report Purchase
